Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16175996 | 1.00 | BACE1 (0.40) | BACE1MEN1POLBKMT2AGAA | |
| SCHEMBL30088347 | 0.87 | BACE1 (0.44) | BACE1GAANLRP3ALDH1A1DHODH | |
| SCHEMBL16176009 | 0.87 | BACE1 (0.44) | BACE1GAANLRP3ALDH1A1DHODH | |
| SCHEMBL16166289 | 0.85 | BACE1 (0.37) | BACE1 | |
| SCHEMBL30088370 | 0.81 | BACE1 (0.53) | BACE1 | |
| SCHEMBL16176007 | 0.81 | BACE1 (0.53) | BACE1 | |
| SCHEMBL16166148 | 0.80 | BACE1 (0.32) | BACE1 | |
| SCHEMBL16166150 | 0.80 | BACE1 (0.32) | BACE1 | |
| SCHEMBL30088443 | 0.80 | BACE1 (0.32) | BACE1 | |
| SCHEMBL16166146 | 0.80 | BACE1 (0.32) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447478-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447478-B2 | BACE1 inhibitors | BACE1, BACE2, APP | BACE1 1/4885MEN1 2611/4885POLB 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.